Overview: NGS Eye Movement Disorders Sequencing TestIntroduction: The NGS Eye Movement Disorders Sequencing Test sequences genes to diagnose eye movement disorders, causing vision issues. Aligned with 2023 AAO guidelines, it uses PCR for high specificity, supporting vision screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected eye movement disorders, such as progressive external ophthalmoplegia.
Other Names: Eye Movement NGS Assay, Eye Movement Disorder Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Eye movement disorder sequencing began in the 2000s with neuro-ophthalmic research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose eye movement disorders, guides treatment, and evaluates patients with vision issues.
Test Parameters: 1. Eye Movement Disorder Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of vision issues, diplopia, or eye movement disorder symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document vision issues, diplopia, ptosis, or family history of eye movement disorders. Include current medications, especially mitochondrial therapies.
Consent: Written consent required, detailing the tests purpose, eye movement disorder implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze eye movement disorder genes (e.g., POLG, TWNK). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for eye movement disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm eye movement disorders, guiding supportive care or genetic counseling. Negative results may require EMG testing.
Specialist Consultation: Consult an ophthalmologist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: EMG, visual field testing, or brain MRI to confirm eye movement disorder diagnosis.
Test Limitations: Not all eye movement disorders are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO Eye Movement Disorder Guidelines, 2023; Neurology, Yu-Wai-Man P, 2022.
